Predictive Clinical Biomarkers Market worth $14.69 billion by 2030 | MarketsandMarkets

DELRAY BEACH, Fla., Jan. 13, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Predictive Clinical Biomarkers Market is projected to grow from about USD 8.49 billion in 2025 to USD 14.69 billion by 2030, at a CAGR of 11.6%.

Browse 708 market data tables and 56 figures spread through 506 pages and an in-depth TOC on "Predictive Clinical Biomarkers Market - Global Forecast to 2030"

Predictive Clinical Biomarkers Market Size & Forecast:

• Market Size Available for Years: 2024–2030
• 2025 Market Size: USD 8.49 billion
• 2030 Projected Market Size: USD 14.69 billion
• CAGR (2025–2030): 11.6%

Predictive Clinical Biomarkers Market Trends & Insights:

• By type, the consumables segment is expected to dominate the market by revenue share.
• By technology, the PCR segment dominate the predictive clinical biomarkers market.
• By application, the cancer segment is expected to dominate the predictive clinical biomarkers market.
• The Asia Pacific predictive clinical biomarkers market was the fastest growing segment with CAGR 13.2% in 2024.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=97566514 

The predictive clinical biomarkers market is experiencing growth due to several key factors, such as the integration of biomarkers into clinical trial design and the increasing adoption of targeted therapies and immunotherapies.

Emerging technologies, including AI-driven analysis of multiplex biomarker data, highly automated IVD workflows, and increasingly sensitive liquid-biopsy assays, are transforming the predictive clinical biomarkers landscape by making complex stratification tests faster and more practical for routine oncology care. At the same time, regulators' emphasis on companion diagnostics and minimal residual disease-style response monitoring is pushing laboratories toward more standardized, clinically validated predictive biomarker panels that directly inform therapy selection, dose adjustment, and real-time tracking of treatment failure or relapse.